Media

This publication describes 3 cases where patients with chronic and recurrent S. aureus-related dermatoses were successfully treated with Staphefekt SA.100, the active ingredient of Gladskin. The results indicate that targeted...

This study shows that the skin-microbiome in patients with eczema/atopic dermatitis is characterized by overgrowth of S. aureus bacteria. More overgrowth was linked to more severe symptoms. On the other hand a...

With Staphefekt, the first targeted therapy against S. aureus is available for long-term daily maintenance therapy, aimed at decreasing the burden of skin colonisation and preventing progression to inflammation and...

These results demonstrate the importance of colonization with S. aureus in Atopic Dermatitis... At present, new targeted antimicrobial therapies (such as lysins) are being developed, which are directed against single...

The endolysin Staphefekt is the active ingredient of Gladskin products and it could play a big role in the maintenance treatment of chronic skin conditions where bacteria are thought to...

A mouse model for atopic dermatitis shows that changes in the skin microbiome corresponded with the disease state. It appears that S. aureus is a major culprit in causing eczema,...

Staphefekt™ targets the unwanted antibiotic resistant Staphylococcus aureus-bacteria and leaves the essential bacteria intact. This bacteria causes or worsens the majority of all skin infections. Read the article on Sky News